Argent BioPharma Limited
RGTLF
$0.0599
$0.011423.51%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.40K | 1.40K | 96.10K | 95.90K | 195.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.40K | 1.40K | 96.10K | 95.90K | 195.40K |
| Cost of Revenue | 1.20K | 1.30K | 220.10K | 219.70K | 171.80K |
| Gross Profit | 200.00 | 200.00 | -124.00K | -123.80K | 23.60K |
| SG&A Expenses | 2.50M | 2.57M | 2.96M | 2.95M | 1.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 154.40K | 158.80K | -554.90K | -553.70K | -1.70K |
| Total Operating Expenses | 2.86M | 2.94M | 3.39M | 3.38M | 2.47M |
| Operating Income | -2.86M | -2.94M | -3.29M | -3.28M | -2.27M |
| Income Before Tax | -3.96M | -4.07M | -3.44M | -3.44M | -2.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.96M | -4.07M | -3.44M | -3.44M | -2.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 100.00 | 100.00 | 5.80K |
| Net Income | -3.96M | -4.07M | -3.44M | -3.44M | -2.31M |
| EBIT | -2.86M | -2.94M | -3.29M | -3.28M | -2.27M |
| EBITDA | -2.70M | -2.77M | -3.12M | -3.11M | -2.09M |
| EPS Basic | -0.08 | -0.08 | -0.07 | -0.07 | -0.10 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.04 | -0.04 | -0.07 |
| EPS Diluted | -0.08 | -0.08 | -0.07 | -0.07 | -0.10 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.04 | -0.04 | -0.07 |
| Average Basic Shares Outstanding | 50.67M | 50.67M | 50.93M | 50.93M | 23.10M |
| Average Diluted Shares Outstanding | 50.67M | 50.67M | 50.93M | 50.93M | 23.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |